If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
130
results.
Updated on
05/11/2025 [07:07:00]
Absstract of: US2025333485A1
This disclosure provides anti-SARS-COV-2 antibodies or antigen-binding fragments thereof targeting the N-terminal domain (NTD) of the spike(S) protein. The disclosed anti-SARS-COV-2 antibodies or antigen-binding fragments thereof have broadly neutralizing activities against several SARS-COV-2 variants of concern. The disclosed anti-SARS-COV-2 antibodies represent a therapeutic strategy in protecting from SARS-COV-2 infections.
Absstract of: US2025333806A1
Disclosed are compositions, assays, methods, diagnostic methods, kits and diagnostic kits for the specific and differential detection of SARS-CoV-2, including SARS-CoV-2 variants, or other coronaviruses from samples including veterinary samples, clinical samples, food samples, forensic sample, an environmental sample (e.g., soil, dirt, garbage, sewage, air, or water), including food processing and manufacturing surfaces, or a biological sample.
Absstract of: WO2025225632A1
The purpose of the present invention is to provide an antiviral agent effective against COVID-19. The purpose can be achieved by (1) a polypeptide that contains an amino acid sequence selected from the group consisting of the amino acid sequence represented by SEQ ID NO: 1, the amino acid sequence represented by SEQ ID NO: 2, the amino acid sequence represented by SEQ ID NO: 3, the amino acid sequence represented by SEQ ID NO: 4, the amino acid sequence represented by SEQ ID NO: 5, the amino acid sequence represented by SEQ ID NO: 6, the amino acid sequence represented by SEQ ID NO: 7, and the amino acid sequence represented by SEQ ID NO: 8, or (2) a polypeptide that has antiviral activity against coronavirus, contains an amino acid sequence in which one amino acid is substituted in the amino acid sequence represented by SEQ ID NO: 1, the amino acid sequence represented by SEQ ID NO: 2, the amino acid sequence represented by SEQ ID NO: 3, the amino acid sequence represented by SEQ ID NO: 4, the amino acid sequence represented by SEQ ID NO: 5, the amino acid sequence represented by SEQ ID NO: 6, the amino acid sequence represented by SEQ ID NO: 7, or the amino acid sequence represented by SEQ ID NO: 8, said polypeptide having an O-glycoside-linked sugar chain.
Absstract of: AU2024234602A1
The present invention is directed to compositions and methods for treating infection with SARS-CoV-2 virus and its sequelae through inhibition of the β-arrestin (arrestin-2) pathway by use of β-adrenergic inverse agonists, particularly including nadolol. The compositions and methods can also employ additional agents to block infection with SARS-CoV-2 virus or inhibit inflammation, particularly inflammation affecting the respiratory tract.
Absstract of: US2025332136A1
Described herein is a composition and methods for treating, reducing the symptoms of, or prophylaxis of viral infections, and particularly SARS-CoV-2. The composition enhances delivery of oxygen to the tissues. Also described herein is a composition and methods for treating cancers, particularly, adenocarcinomas, infiltrating ductal adenocarcinoma, metastatic ductal adenocarcinoma, and neuroendocrine tumors. The composition inhibits the growth of tumor cells and promotes cytoreduction of tumors.
Absstract of: US2025332177A1
A methylene blue COVID-19 composition for treating short-term and long-term COVID-19 symptoms. The methylene blue COVID-19 composition consists of methylene blue and aspirin. The amount of methylene blue in the overall composition is in the range of about 50 mg to 300 mg, while the amount of aspirin in the overall composition is in the range of about 80 mg to 350 mg. The methylene blue COVID-19 composition is formed as a powder that is dissolvable in water or another beverage for patient consumption. The overall composition is used as a treatment for up to about 6 months after testing positive for a COVID-19 infection, in order to effectively treat various symptoms of COVID-19 infections. The methylene blue COVID-19 composition is dissolved in liquid to be a standalone methylene blue COVID-19 solution. In one embodiment, the methylene blue COVID-19 composition is in a pill form.
Absstract of: US2025332220A1
The present invention relates to a method for treating and/or preventing pneumonia, including administering a therapeutically effective amount of cerebral dopamine neurotrophic factor (CDNF) to a subject in need thereof. The pneumonia is caused by infection of influenza A virus or severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Absstract of: US2025332170A1
Compositions for and methods of treating lung conditions, such as those associated with elevated cytokines, are described. The methods include administration of vandetanib or a pharmaceutically acceptable salt thereof. Methods of treating COVID-19 via administration of vandetanib or a pharmaceutically acceptable salt thereof are also described. Administration of vandetanib can reduce levels of cytokines that are elevated in subjects suffering from COVID-19 and mitigate or eliminate the cytokine storm associated with severe cases of COVID-19.
Absstract of: US2025332162A1
The present invention is generally directed to a potent therapy for SARS-CoV-2 (CoV2) disease which may involve combinations of agents. Here we describe combinations of 2, 3 or more drugs wherein the combination inhibits CoV2 replication through one or more mechanisms of action and increases potency of nucleoside and nucleotide analog drugs through inhibition of cellular enzymes involved in purine nucleotide biosynthesis. The combinations may be delivered as individual doses, concurrent dosing, or co-formulation of 2 or more agents. The inventive aspect includes identified components, the ratios among identified components and treatment regimens for reducing morbidity and mortality of CoV2 infection. Further claimed are drug formulations and methods of delivery.
Absstract of: US2025332247A1
The present disclosure provides a glycoengineered SARS-COV-2 spike protein which is capable of eliciting an enhanced immune response relative to a native spike protein of SARS-COV-2 and its variants. The glycoengineered spike protein exposes the glycosylation sites and at the same time preserves the tertiary structure of the spike protein. The present disclosure therefore provides improved immunogens, vaccines, and methods for better prevention and treatment of the emerging coronavirus infections.
Absstract of: US2025333452A1
Provided herein are SARS-CoV-2 spike proteins and polypeptides (e.g., SARS-CoV-2 spike proteins and polypeptide immunogens (and immunogenic fragments and immunogenic variants thereof)) comprising at least one set of amino acid substitutions, and nucleic acid molecules encoding the same. Further provided herein are compositions (e.g., pharmaceutical compositions) and vaccines comprising the same for use in e.g., the prevention, treatment, and/or amelioration of a SARS-CoV-2 infection; vaccination against SARS-CoV-2.
Absstract of: US2025333809A1
Disclosed are oligonucleotide primers that hybridize specifically with any base sequence designed from the base sequences of the N gene, RNA-dependent RNA polymerase gene, M gene, and S gene of SARS-COV-2, a nucleic acid amplification method using said primers, a test method for SARS-COV-2 infection by detection of nucleic acid amplification, and a COVID-19 test kit.
Absstract of: EP4640230A1
An application of Shenling Baizhu in the preparation of a medicine for treating neuropsychiatric symptoms of recovered COVID-19 patients.
Absstract of: WO2024133564A1
: SARS-CoV-2 spike protein-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the SARS-CoV-2 spike protein-binding molecules.
Absstract of: WO2024137381A1
Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies. In some aspects, the antibodies bind a BA.4 or BA.5 variant. In other aspects, the antibodies bind BQ1.1 and/or XBV.
Absstract of: EP4641196A1
Disclosed is a CRISPR/Cas based system for screening an RNA aptamer against a target protein, comprising: (i) a guide RNA comprising a recognition sequence and a nucleic acid aptamer random library having a predetermined length; (ii) a target sequence complementary to the recognition sequence of the guide RNA; (iii) a selection marker located downstream of the target sequence and comprising a basal promoter and a selection marker gene; (iv) a fusion protein comprising the target protein and a transcriptional activation module, wherein a binding of the target protein to an RNA aptamer of the nucleic acid aptamer random library results in recruitment of the transcriptional activation module to the selection marker; (v) a dCas protein specifically recognizing the target sequence under the guidance of the guide RNA; and (vi) a screening cell. Also disclosed is a method for screening an RNA aptamer against a target protein using the system provided herein and RNA aptamers against S1 protein of SARS-CoV-2 virus and applications thereof.
Absstract of: LU601360B1
A Chinese medicine formula for COVID-19, comprising the following raw materials by weight ratio: 25 grams of siraitia grosvenorii flower, 10 grams to 20 grams of ligustrum lucidum, 5 grams to 10 grams of winter mulberry leaves, 8 grams to 15 grams of Chinese mahonia, 5 grams to 10 grams of Dizhu leaves, 5 grams to 10 grams of gardenia jasminoides, 3 grams to 8 grams of astragalus membranaceus, 3 grams to 8 grams of gentiana, 5 grams to 10 grams of ophiopogon japonicus, 2 grams to 6 grams of cassia twig, 3 grams to 8 grams of artemisia argyi leaves, and 10 grams to 15 grams of hairy holly. Based on the in-depth analysis of the pathogenesis characteristics of COVID-19, the invention achieves a comprehensive improvement of the symptoms of the COVID-19 by reasonable compatibility of a variety of Chinese medicinal materials; wherein, the combination of siraitia grosvenorii flower and ligustrum lucidum significantly improves the symptoms of dry throat and cough; winter mulberry leaves and Chinese mahonia can synergistically reduce fever quickly; the invention is suitable for various symptoms such as headache, fever, sore throat, chest tightness, cough (dry cough) caused by the COVID-19; generally, it turns from positive to negative in 3 to 4 days, and it takes 5 days to 8 days to eliminate all the symptoms mentioned hereinabove, depending on the physical condition of each person.
Absstract of: US12453717B1
The present disclosure relates to a method of reducing or arresting viral load in a subject infected with a coronavirus, the method comprising the step of administering to the subject a therapeutically effective amount of a viral protease inhibitor. In some embodiments, the subject is a human. In one embodiment, the coronavirus is SARS-CoV-19 and the viral protease inhibitor is frovatriptan (6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide.
Absstract of: US2025325652A1
Provided are an isolated polypeptide or an antigenic fragment thereof, an antibody binding to the isolated polypeptide or the antigenic fragment thereof, a composition including the isolated polypeptide or the antigenic fragment thereof, and an array including the isolated polypeptide or the antigenic fragment thereof. Further provided a method for detecting the presence of an antibody against SARS-COV-2 in a subject, a method for the prognosis of the subject infected with SARS-COV-2, a method for inducing an immune response against SARS-CoV-2 in a subject, and a method for preventing and/or treating a disease caused by SARS-COV-2 infection in a subject.
Absstract of: US2025327052A1
The invention relates to recombinant mutated angiotensin converting enzyme 2 (ACE2) comprising one or more amino acid substitutions at amino acid positions T27, F28, K31, H34, Y41 and Q42 which have improved binding affinity to SARS-CoV-1 and/or SARS-CoV-2. It also relates to combinatorial mutant ACE2 comprising T27Y/K31 H/H34A, T27YZ K31 H/H134V and T27Y/K31 Y/H134V and the use of said mutant ACE2 for treating and preventing coronavirus infection.
Absstract of: US2025327038A1
Attenuate coronavirus species that are able to fully replicate and spread are proposed together with the methods of obtaining thereof. The proposed coronavirus species are intended to treat and prevent viral infections including all those caused by coronavirus species that affect humans as the COVID-19 caused by the SARS-CoV2. Compared with other treatment or vaccine alternatives, the availability of such attenuate coronavirus species does not require of significant distribution and production resources. Some of the embodiments of the invention involve the use of the attenuate coronavirus species in formulations or compositions that have to be approved as safe and effective for therapeutic use in specific territories by a valid regulatory agency as the Food and Drug Agency (FDA) in the United States.
Absstract of: WO2025218020A1
Provided are a SARS-CoV-2 camelid-derived nanobody or an antigen-binding fragment thereof, and a composition thereof and a use thereof. The nanobody has at least 95% homology to SEQ ID NO: 1. Mutation engineering of the multivalent nanobody obtained by screening and purifying provides a method for rapidly generating an efficient virus neutralizing agent, such that viral escape mutants can be effectively controlled.
Absstract of: US2025327039A1
Attenuate coronavirus species that are able to fully replicate and spread are proposed together with the methods of obtaining thereof. The proposed coronavirus species are intended to treat and prevent viral infections including all those caused by coronavirus species that affect humans as the COVID-19 caused by the SARS-CoV2. Compared with other treatment or vaccine alternatives, the availability of such attenuate coronavirus species does not require of significant distribution and production resources. Some of the embodiments of the invention involve the use of the attenuate coronavirus species in formulations or compositions that have to be approved as safe and effective for therapeutic use in specific territories by a valid regulatory agency as the Food and Drug Agency (FDA) in the United States.
Absstract of: US2025326715A1
The invention provides novel compounds that are potent inhibitors of main protease (MPro) and pharmaceutical compositions and methods thereof for treating MPro-associated or mediated diseases and conditions, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).
Nº publicación: US2025325535A1 23/10/2025
Applicant:
THE UNIV OF HONG KONG [HK]
CENTRE FOR VIROLOGY VACCINOLOGY AND THERAPEUTICS LTD [HK]
The University of Hong Kong,
Centre for Virology, Vaccinology and Therapeutics Limited
Absstract of: US2025325535A1
This invention provides a novel small-molecule allosteric protease inhibitor, 10-(4-methylphenyl)-7-phenyl-6,7,8,10-tetrahydro-5H-indeno1,2-bquinoline-9,11-dione, which exhibits the highest selectivity index (SI), and shows inhibition against several SARS-CoV-2 variants of concern (VOC) and multiple human coronaviruses including MERS-CoV, SARS-CoV, and HCoV-229E. Not only does it demonstrate antiviral potency against a wide spectrum of coronavirus strains and species, but it also shows drug synergism with nirmatrelvir, which could be used in combination therapy to not only treat coronavirus-caused infections and diseases, but also lower the risk of antiviral resistance.
BOPI
Electronic site
